PDUFA Date

The FDA's target deadline to decide on a drug application, a binary catalyst that can double or halve biotechs.

Also known as: PDUFA Goal Date, FDA Action Date

What it is

A PDUFA date is the target date by which the FDA aims to complete its review of a new drug or biologic application under the Prescription Drug User Fee Act. It sets a rough calendar for an approval decision. The outcome can be approval, rejection, or a delay.

What it does

PDUFA dates are calendar-scheduled binary catalysts: approval can send a small biotech soaring, a complete response letter can crater it. Investors build event-driven strategies around them. Implied volatility spikes into the date.

The evidence

Small-cap biotechs routinely gap up or down double digits on PDUFA decisions and complete response letters.

Best for

Clinical-stage biotechs; broad exposure via XBI, IBB.

Pairs well with

fda-approval, event-driven, catalyst

Use cautiously with

The FDA can miss or extend a PDUFA date without a decision, and approval does not guarantee commercial success.

Cautions

Options are expensive into the date and IV crush can erase gains even on a favorable move.